Applications of 1,2-O-Isopropylidene-Alpha-D-Xylofuranose in Industrial Manufacturing

As a direct manufacturer, we supply 1,2-O-Isopropylidene-Alpha-D-Xylofuranose primarily to specialized sectors that rely on quality-proven carbohydrate intermediates. This protected sugar finds critical roles in advanced synthesis and industrial downstream processes. Our focus is on sectors where stringent chemical identity and purity assurance define value in finished products.

1. Nucleoside and Nucleotide Synthesis for Pharmaceutical Intermediates

Pharmaceutical manufacturers utilize this compound as a key protected pentose in the synthesis of modified nucleosides and nucleotides, which serve as core building blocks for antiviral and anticancer active pharmaceutical ingredients (APIs). Its acetone protection allows selective glycosylation and downstream deprotection under controlled conditions. Material batches must deliver reliably low residual solvent and controlled moisture content to prevent unwanted side-reactions in oligonucleotide chain assembly or further API elaboration.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP) guidelines (21 CFR 210/211)
• International Conference on Harmonisation Q7 (ICH Q7) for pharmaceutical intermediates
• European Pharmacopoeia monograph 2.2.46 (if used for synthetic ribonucleosides)
• USP-NF General Chapter <923> Residual Solvents

Typical usage ratio

• Used in stoichiometric ratios (1:1 or excess) with nucleobase or aglycone reactants
• Ratio adjusted according to targeted yield and minimization of side-reaction profile, typical range 0.9–1.2 equivalents per nucleobase substrate

Downstream process integration

• Introduced at the glycosylation stage, following protection of other hydroxyl groups as needed
• Neutral or mild acidic conditions deployed to enable selective N-glycosidic bond formation
• Subsequent deprotection and purification steps performed before final API crystallization or lyophilization

Final product types

• Synthetic nucleoside reverse transcriptase inhibitors (e.g., Lamivudine, Emtricitabine)
• Anticancer nucleoside analogs
• RNA and DNA oligonucleotide drug substances
• Diagnostic nucleic acid probes

2. Carbohydrate Chemistry for Fine Chemical Synthesis

Manufacturing chemists employ this raw material as a masked precursor in regioselective functionalization of pentoses. The isopropylidene group stabilizes the furanose ring and simplifies the installation of specific substituents at C-3, C-4, or C-5 positions under basic or acidic catalysis. Batch traceability and full impurity profiles are required for compliance with specialty chemical sector requirements, especially in developing rare sugar derivatives, chiral ligands, and specialty monomers.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (EC No 1907/2006)
• Technical Data Sheets and in-house QC release specifications

Typical usage ratio

• Deployed as the core pentose substrate in 1.0–1.5 molar equivalents
• Adjusted depending on the target functional group transformation yield and process scale

Downstream process integration

• Protecting group remains intact during most functionalization stages
• Operators remove the isopropylidene group at late-stage conversion using aqueous acid hydrolysis
• Material integrated before oxidation, reduction or halogenation reactions targeting specific ring positions

Final product types

• Rare sugar analogs
• Chiral pool ligands for organometallic catalysis
• Specialty resins and monomers
• Building blocks for pharmaceutical lead compounds

3. Synthesis of Sugar-Based Surfactants

Producers of high-value sugar-based surfactants exploit the structure to manufacture specialty detergents and emulsifiers for use in personal care or biotechnical processes. The protected xylofuranose enables precise glycosylation and controlled branching, enhancing surfactant head-group identity. Strict quality audits determine feedstock acceptance, as product safety and traceability must align with regulatory demands for ingredients in cosmetic or food-contact formulations.

Industry compliance standards

• REACH compliance (Europe)
• OECD Guidelines for the Testing of Chemicals
• Cosmetic Ingredient Review (CIR) reporting for INCI-registered surfactants (where applicable)
• ISO 22716:2007 Cosmetics—Good Manufacturing Practices

Typical usage ratio

• Usage varies, typically 0.5–1.3 equivalents relative to the alcohol or fatty acid component in glycosylation reactions
• Modified depending on the hydrophilic–lipophilic balance (HLB) required by the final surfactant specification

Downstream process integration

• Charged into reaction tanks at initial surfactant head-group assembly
• Protection retained through initial coupling, followed by deprotection prior to final product isolation
• Product typically passes through silica column purification before downstream formulation

Final product types

• Nonionic alkylglycoside surfactants
• Specialty emulsifiers for personal care products
• Food contact cleansing agents
• Laboratory detergents

4. Glycoconjugate Synthesis for Biomedical Research

Research and development divisions within biotechnology and diagnostics companies source this protected xylofuranose as a sugar donor in the chemical synthesis of complex glycoconjugates. High purity and absence of colored impurities are mandatory, since downstream coupling efficiency with peptides or lipids impacts the accuracy of immunological assays and therapeutic candidate synthesis. Glycoconjugate APIs and probes produced require documentation supporting all process chemicals and potential trace contaminants.

Industry compliance standards

• GLP (Good Laboratory Practice) for research-scale batches
• ISO 13485:2016 for medical device component manufacture
• Material traceability for biopharmaceutical validation (where applicable)
• TSE/BSE-free verification for animal-exclusion in pharmaceutical research

Typical usage ratio

• Serves as the primary carbohydrate donor, typically 1.0–1.5 equivalents per nucleophile acceptor (peptide or amine-reactant)
• Excess can be required if coupling step suffers from incomplete activation

Downstream process integration

• Added to the reaction following pre-activation with coupling agents (e.g., DCC, EDC)
• Isopropylidene group removed during final purification to expose free hydroxyl groups for biological function
• Mobilized onto solid supports for parallel synthesis when required for custom array production

Final product types

• Glycopeptide immunogens
• Synthetic glycosphingolipids
• Diagnostic glycan microarrays
• Carbohydrate-based vaccine prototypes